Systematic Review of Neoadjuvant Immunotherapy for Patients With Non-Small Cell Lung Cancer.

ABSTRACT: There is a paucity of robust clinical evidence for the role of neoadjuvant immunotherapy in patients with resectable non-small cell lung cancer. The primary aim of the study was to identify the available data on the feasibility, safety and efficacy of neoadjuvant immunotherapy. A systematic review was conducted using electronic databases. Relevant studies were identified according to predefined selection criteria. Five relevant publications on 4 completed trials were identified. In most studies, >90% of patients were able to undergo surgery within the planned timeframe after neoadjuvant immunotherapy. There was a high incidence of open thoracotomy procedures, either planned or converted from a planned minimally invasive approach. Mortality ranged from 0 to 5%, but none of the reported deat

SUBMITTER: Cao C 

PROVIDER: S-EPMC8273189 | biostudies-literature | 2021 Autumn

REPOSITORIES: biostudies-literature